Logo image of XERS

XERIS BIOPHARMA HOLDINGS INC (XERS) Stock Price, Quote, News and Overview

NASDAQ:XERS - Nasdaq - US98422E1038 - Common Stock - Currency: USD

6.84  +0.24 (+3.64%)

After market: 6.8399 0 (0%)

XERS Quote, Performance and Key Statistics

XERIS BIOPHARMA HOLDINGS INC

NASDAQ:XERS (8/8/2025, 8:12:48 PM)

After market: 6.8399 0 (0%)

6.84

+0.24 (+3.64%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High7.09
52 Week Low2.21
Market Cap1.10B
Shares160.16M
Float153.34M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE60.96
Earnings (Next)11-06 2025-11-06/bmo
IPO06-21 2018-06-21


XERS short term performance overview.The bars show the price performance of XERS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80

XERS long term performance overview.The bars show the price performance of XERS in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of XERS is 6.84 USD. In the past month the price increased by 33.86%. In the past year, price increased by 194.83%.

XERIS BIOPHARMA HOLDINGS INC / XERS Daily stock chart

XERS Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 38.74 592.95B
JNJ JOHNSON & JOHNSON 17.33 417.44B
AZN ASTRAZENECA PLC-SPONS ADR 16.57 228.04B
NVO NOVO-NORDISK A/S-SPONS ADR 12.96 226.97B
NVS NOVARTIS AG-SPONSORED ADR 13.2 226.19B
MRK MERCK & CO. INC. 10.48 202.62B
PFE PFIZER INC 7.25 139.75B
SNY SANOFI-ADR 10.66 114.95B
BMY BRISTOL-MYERS SQUIBB CO 6.83 93.51B
GSK GSK PLC-SPON ADR 8.36 76.27B
ZTS ZOETIS INC 23.69 65.60B
TAK TAKEDA PHARMACEUTIC-SP ADR 48.13 45.60B

About XERS

Company Profile

XERS logo image Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company is headquartered in Chicago, Illinois and currently employs 394 full-time employees. The company went IPO on 2018-06-21. The company has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. The company also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. The company is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

Company Info

XERIS BIOPHARMA HOLDINGS INC

1375 West Fulton Street, Suite 1300

Chicago ILLINOIS 60601 US

CEO: Paul R. Edick

Employees: 394

XERS Company Website

XERS Investor Relations

Phone: 18444455704

XERIS BIOPHARMA HOLDINGS INC / XERS FAQ

What is the stock price of XERIS BIOPHARMA HOLDINGS INC today?

The current stock price of XERS is 6.84 USD. The price increased by 3.64% in the last trading session.


What is the ticker symbol for XERIS BIOPHARMA HOLDINGS INC stock?

The exchange symbol of XERIS BIOPHARMA HOLDINGS INC is XERS and it is listed on the Nasdaq exchange.


On which exchange is XERS stock listed?

XERS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for XERIS BIOPHARMA HOLDINGS INC stock?

12 analysts have analysed XERS and the average price target is 6.71 USD. This implies a price decrease of -1.83% is expected in the next year compared to the current price of 6.84. Check the XERIS BIOPHARMA HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is XERIS BIOPHARMA HOLDINGS INC worth?

XERIS BIOPHARMA HOLDINGS INC (XERS) has a market capitalization of 1.10B USD. This makes XERS a Small Cap stock.


How many employees does XERIS BIOPHARMA HOLDINGS INC have?

XERIS BIOPHARMA HOLDINGS INC (XERS) currently has 394 employees.


What are the support and resistance levels for XERIS BIOPHARMA HOLDINGS INC (XERS) stock?

XERIS BIOPHARMA HOLDINGS INC (XERS) has a support level at 5.17. Check the full technical report for a detailed analysis of XERS support and resistance levels.


Is XERIS BIOPHARMA HOLDINGS INC (XERS) expected to grow?

The Revenue of XERIS BIOPHARMA HOLDINGS INC (XERS) is expected to grow by 33.98% in the next year. Check the estimates tab for more information on the XERS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy XERIS BIOPHARMA HOLDINGS INC (XERS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does XERIS BIOPHARMA HOLDINGS INC (XERS) stock pay dividends?

XERS does not pay a dividend.


When does XERIS BIOPHARMA HOLDINGS INC (XERS) report earnings?

XERIS BIOPHARMA HOLDINGS INC (XERS) will report earnings on 2025-11-06, before the market open.


What is the Price/Earnings (PE) ratio of XERIS BIOPHARMA HOLDINGS INC (XERS)?

XERIS BIOPHARMA HOLDINGS INC (XERS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.21).


What is the Short Interest ratio of XERIS BIOPHARMA HOLDINGS INC (XERS) stock?

The outstanding short interest for XERIS BIOPHARMA HOLDINGS INC (XERS) is 12.75% of its float. Check the ownership tab for more information on the XERS short interest.


XERS Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to XERS. When comparing the yearly performance of all stocks, XERS is one of the better performing stocks in the market, outperforming 97.23% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

XERS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to XERS. Both the profitability and financial health of XERS have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

XERS Financial Highlights

Over the last trailing twelve months XERS reported a non-GAAP Earnings per Share(EPS) of -0.21. The EPS increased by 51.16% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -14.29%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%90%
Sales Q2Q%48.84%
EPS 1Y (TTM)51.16%
Revenue 1Y (TTM)23.89%

XERS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to XERS. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of 76.38% and a revenue growth 33.98% for XERS


Ownership
Inst Owners54.38%
Ins Owners2.91%
Short Float %12.75%
Short Ratio9.77
Analysts
Analysts85
Price Target6.71 (-1.9%)
EPS Next Y76.38%
Revenue Next Year33.98%